We sought to perform a genomic evaluation of the risk of incident cancer in statin users, free of cancer at study entry. Patients who previously participated in two phase IV trials (TNT and IDEAL) with genetic data were used (n = 11,196). A GWAS meta-analysis using Cox modeling for the prediction of incident cancer was conducted in the pooled cohort and sex-stratified. rs13210472 (near HLA-DOA gene) was associated with higher risk of incident cancer amongst women with prevalent coronary artery disease (CAD) taking statins (hazard ratio [HR]: 2.66, 95% confidence interval [CI]: 1.88-3.76, P = 3.5 × 10). Using the UK Biobank and focusing exclusively on women statin users with CAD (n= 2952), rs13210472 remained significantly associated with incident cancer (HR: 1.71, 95% CI: 1.14-2.56, P = 9.0 × 10). The association was not observed in non-statin users. In this genetic meta-analysis, we have identified a variant in women statin users with prevalent CAD that was associated with incident cancer, possibly implicating the human leukocyte antigen pathway.
References
Taylor F, Huffman M, Macedo A, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;31:CD004816.
Silverman M, Ference B, Im K, Wiviott S, Giugliano R, Grundy S, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions a systematic review and meta-analysis. JAMA. 2016;316:1289–97.
[PMID: 27673306]
Cholesterol Treatment Trialists (CTT) Collaborators. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7:e29849.
[DOI: 10.1371/journal.pone.0029849]
Wenger N, Lewis S, Welty F, Herrington D, Bittner V.TNT Steering Committee and Investigators Beneficial effects of aggressive low-density liprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. BMJ. 2007;94:434–9.
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T.Cholesterol and Recurrent Events Trial investigators et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996;335:1001–9.
[PMID: 8801446]
Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the west of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–86.
[PMID: 17928595]
Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.
[PMID: 12457784]
Blais L, Desgagné A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. JAMA Intern Med. 2000;160:2363–8.
[DOI: 10.1001/archinte.160.15.2363]
Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. EJC. 2008;44:2122–32.
[DOI: 10.1016/j.ejca.2008.06.025]
Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92.
[PMID: 15917383]
Tran KT, McMenamin ÚC, Coleman HG, Cardwell CR, Murchie P, Iversen L, et al. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer. 2020;146:1250–60. https://doi.org/10.1002/ijc.32426 . Epub 4 Jun 2019.
[DOI: 10.1002/ijc.32426]
LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.
[PMID: 15755765]
Pedersen T, Faergeman O, Kastelein J, Olsson A, Tikkanen M, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.
[PMID: 16287954]
Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am J Cardiol. 2004;94:720–4.
[PMID: 15374773]
Waters D, Guyton J, Herrington D, McGowan M, Wenger N, Shear C, et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93:154–8.
[PMID: 14715339]
Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun. 2019;10:1891. https://doi.org/10.1038/s41467-019-09572-5 .
[DOI: 10.1038/s41467-019-09572-5]
Lemieux-Perreault L, Legault M, Asselin G, Dubé M. Genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools. Bioinformatics. 2016;32:3661–3.
[PMID: 27497439]
Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. BMC Bioinforma. 2010;11:288.
[DOI: 10.1186/1471-2105-11-288]
Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
[PMID: 12958120]
Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. StatMed. 2002;21:1539–58.
Cochran W. The combination of estimates from different experiements. Biometrics. 1954;10:101–29.
[DOI: 10.2307/3001666]
Nelson CP, Goel AA-O, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. (1546–1718 (Electronic)).
Meijers W, Boer R. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115:844–53.
[PMID: 30715247]
Shiina T, Hosomichi K, Inoko H, Kulski J. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54:15–39.
[PMID: 19158813]
Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics. 2016;32:3207–9.
[PMID: 27318201]
Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics. 2019;35:4851–3.
[PMID: 31233103]
Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B, et al. HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol. 2019;10:1081.
[PMID: 31156634]
Chemin K, Gerstner C, Malmström V. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front Immunol. 2019;10:353.
[PMID: 30915067]
Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45.
[PMID: 18433475]
Capone I, Marchetti P, Ascierto PA, Malorni W, Gabriele L. Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy. Front Immunol. 2018;9:552.
[PMID: 29619026]
van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7:12.
[PMID: 19331649]
Nair B, Taylor-Gjevre R, Wu L, Jin S, Quail JM. Incidence and prevalence of rheumatoid arthritis in Saskatchewan, Canada: 2001-2014. BMC Rheumatol. 2019;3:28.
[PMID: 31360913]
Frostegård J, Zhang Y, Sun J, Yan K, Liu A. Oxidized low‐density lipoprotein (OxLDL)–treated dendritic cells promote activation of T cells in human atherosclerotic plaque and blood, which is repressed by statins: microRNA let‐7c is integral to the effect. J Am Heart Assoc. 5:e003976.
Nadiminty N, Tummala R, Lou W, Zhu Y, Shi X-B, Zou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE. 2012;7:e32832.
[PMID: 22479342]
Mizuno R, Kawada K, Sakai Y. The molecular basis and therapeutic potential of Let-7 MicroRNAs against colorectal cancer. Can J Gastroenterol Hepatol. 2018;2018:5769591.
[PMID: 30018946]
Biamonte F, Santamaria G, Sacco A, Perrone FM, Di Cello A, Battaglia AM, et al. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Sci Rep. 2019;9:5668.
[PMID: 30952937]
Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 2014;342:43–51.
[PMID: 23981581]
Coussens L, Werb Z. Inflammation and cancer. Nature. 2010;420:860–7.
[DOI: 10.1038/nature01322]
Rhodes DA, Trowsdale J. Genetics and molecular genetics of the MHC. Rev Immunogenet. 1999;1:21–31.
[PMID: 11256569]
Nangalia J, Campbell PJ. Genome sequencing during a patient’s journey through cancer. N Engl J Med. 2019;381:2145–56.
[PMID: 31774959]
Trowsdale J. Genomic structure and function in the MHC. Trends Genet. 1993;9:117–22.
[PMID: 8516845]
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5:889–99.
[PMID: 15573121]
Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41:1–12.
[PMID: 24004450]
Busch R, De Riva A, Hadjinicolaou AV, Jiang W, Hou T, Mellins ED. On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Exp Rev Mol Med. 2012;14:e15–e15.
[DOI: 10.1017/erm.2012.9]
Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol. 2013;25:81–89.
[PMID: 23141566]
Kennedy AE, Ozbek U, Dorak MT. What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017;44:195–211.
[PMID: 28877428]
Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
[PMID: 15843671]
Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
[DOI: 10.1126/science.1203486]
